HIV vaccine - Crucell/IAVI/Beth Israel Deaconess Medical Center

Drug Profile

HIV vaccine - Crucell/IAVI/Beth Israel Deaconess Medical Center

Alternative Names: Ad26.ENVA.01 HIV vaccine; AdVac®/PER.C6® Technology-based HIV vaccine; HIV-vaccine-Ad26-ENVA-01; rAd26 vaccine

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell
  • Developer Crucell; International AIDS Vaccine Initiative
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 23 Jul 2016 Crucell withdraws a phase I trial in HIV infections (Prevention, In volunteers) in Uganda prior to enrolment (PACTR201304000534302)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention, In volunteers) in Kenya (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention, In volunteers) in Rwanda (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top